Thermo Fisher Scientific (TMO)
(Delayed Data from NYSE)
$618.46 USD
-5.75 (-0.92%)
Updated Sep 11, 2024 04:00 PM ET
After-Market: $618.47 +0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$618.46 USD
-5.75 (-0.92%)
Updated Sep 11, 2024 04:00 PM ET
After-Market: $618.47 +0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum C VGM
Zacks News
Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. In Nov 2006, Thermo Fisher Scientific, Inc. was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. On Feb 3, 2014, Thermo Fisher acquired Life Technologies Corporation. Following the acquisition, the new reporting segments are: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Thermo Fisher's (TMO) Oncomine Dx Gets CDx Approval for TIBSOVO
by Zacks Equity Research
Thermo Fisher (TMO) receives FDA go-ahead for the Oncomine Dx Target Test as a CDx for Servier's ivosidenib tablets, TIBSOVO.
Thermo Fisher Scientific (TMO) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Thermo Fisher Scientific (TMO) closed at $552.77 in the latest trading session, marking a +0.86% move from the prior day.
Agilent (A) Boosts PD-L1 IHC 22C3 pharmDX Assay Use in Europe
by Zacks Equity Research
Agilent Technologies (A) boosts presence in the companion diagnostics market by expanding the use of PD-L1 IHC 22C3 pharmDx assay for esophageal cancer treatment in Europe.
Here's Why You Should Hold on to Thermo Fisher (TMO) for Now
by Zacks Equity Research
Investors are optimistic about Thermo Fisher (TMO) on robust segmental growth and raised 2021 guidance.
The Zacks Analyst Blog Highlights: Thermo Fisher Scientific, McDonald's, Union Pacific Corp, Gilead Sciences and Uber
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Thermo Fisher Scientific, McDonald's, Union Pacific Corp, Gilead Sciences and Uber
Top Stock Reports for Thermo Fisher, McDonald's & Union Pacific
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Thermo Fisher Scientific Inc. (TMO), McDonald's Corporation (MCD), and Union Pacific Corporation (UNP).
Thermo Fisher (TMO) Hits a 52-Week High: What's Driving It?
by Zacks Equity Research
Strong performance by the four reported business segments is driving the top line for Thermo Fisher (TMO).
4 Medical Device Stocks Set to Beat This Earnings Season
by Urmimala Biswas
Rebound in base sales makes us optimistic about HSIC, XRAY, GMED and ABC's results this time around.
Thermo Fisher (TMO) Beats on Q2 Earnings, Raises 2021 View
by Zacks Equity Research
Thermo Fisher's (TMO) base business witnesses accelerated growth in the second quarter.
Thermo Fisher Scientific (TMO) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Thermo Fisher (TMO) delivered earnings and revenue surprises of 1.63% and 5.92%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Medical Device Stocks' Earnings on Jul 28: TMO, ALGN & More
by Urmimala Biswas
The sector's Q2 results are likely to reflect solid earnings and revenue growth on strong base business recovery.
Thermo Fisher (TMO) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
With vaccine rollouts through Q2, Thermo Fisher's (TMO) Life-Science Solutions segment is likely to have registered top-line contributions from vaccine and therapy production supplies.
Healthcare ETFs in Focus as Q2 Earnings Unfold
by Sweta Killa
The healthcare sector has been benefiting from COVID-19 vaccines or treatment with many more to come.
Thermo Fisher Scientific (TMO) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Thermo Fisher (TMO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Thermo Fisher Scientific (TMO) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Thermo Fisher Scientific (TMO) closed at $522.58, marking a +0.18% move from the previous day.
Why Thermo Fisher (TMO) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Thermo Fisher (TMO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Thermo Fisher (TMO) Advances Customer Research With New Launch
by Zacks Equity Research
Thermo Fisher's (TMO) new instrument enables high-resolution images of nanoparticles and beam-sensitive materials to be obtained from a commercially available desktop SEM.
Thermo Fisher (TMO) to Meet Plasmid DNA Demand With New Facility
by Zacks Equity Research
Thermo Fisher's (TMO) new facility will manufacture materials that are essential for production of plasmid-based therapies and vaccines.
Thermo Fisher's (TMO) New Pact Drives Sustainable Lab Practices
by Zacks Equity Research
Thermo Fisher (TMO) expects to ACT label more than 1,200 additional SKUs to allow research, pharmaceutical and clinical laboratories to achieve their sustainability objectives.
Thermo Fisher's (TMO) Rapid DNA Solution Gets FBI Approval
by Zacks Equity Research
Thermo Fisher's (TMO) RapidHIT ID DNA Booking System allows seamless integration of Rapid DNA into the law enforcement booking agency process.
Thermo Fisher (TMO) Introduces CoE in Clinical Metabolomics
by Zacks Equity Research
Thermo Fisher's (TMO) new research collaboration is aimed to provide the metabolomics community with advanced, best practices and standard operating procedures.
The Zacks Analyst Blog Highlights: Salesforce, Thermo Fisher Scientific, Royal Dutch Shell, Citigroup and Starbucks
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Salesforce, Thermo Fisher Scientific, Royal Dutch Shell, Citigroup and Starbucks
Top Stock Reports for salesforce, Thermo Fisher & Royal Dutch Shell
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including salesforce (CRM), Thermo Fisher Scientific (TMO), and Royal Dutch Shell (RDS.A).
Agilent (A) Expands Presence in LC Market With New Systems
by Zacks Equity Research
Agilent (A) expands its Bio Liquid Chromatography solutions portfolio with three new systems to fulfil the needs of biopharma industry.
Here's How Much a $1000 Investment in Thermo Fisher Scientific Made 10 Years Ago Would Be Worth Today
by Zacks Equity Research
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.